Zydus Lifesciences bags USFDA nod for Metronidazole topical cream to treat skin disorder
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad, India.
Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Metronidazole Topical Cream, 0.75% (USRLD: MetroCream, 0.75%).
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea, a type of adult acne. It is expected to help decrease redness, swelling and the number of pimples caused by rosacea and is believed to work by decreasing swelling (inflammation).
The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India).
Read also: USFDA approves Zydus Lifesciences Icosapent Ethyl Capsules
Metronidazole Topical Cream, 0.75% had annual sales of USD 25 mn in the United States (IQVIA MAT Feb. 2023).
Medical Dialogues team had earlier reported that the company had received final approval from the USFDA to market Ivermectin Cream, 1%. USRLD: Soolantra. Ivermectin Cream is used for the treatment of inflammatory lesions of rosacea.
Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), an Indian Pharmaceutical company is a fully integrated, global healthcare provider. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.
